Jeremy Skillington of Poolbeg Pharma: First time RSV drug candidates have been identified using AI
Episode 1086, Dec 21, 2022, 07:25 AM
Jeremy Skillington CEO of Poolbeg Pharma #POLB discusses how their cutting edge AI program, in collaboration OneThree Biotech, has identified RSV drug candidates, a first for the industry.
Highlights
Poolbeg Pharma , a leading infectious disease focused biopharmaceutical company, announces that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus ('RSV') artificial intelligence ('AI') Programme with OneThree Biotech, Inc.
Since initiating the collaboration in February 2022, Poolbeg's scientific team has worked closely with OneThree to build a tailored AI approach that leverages Poolbeg's unique RSV human challenge trial data in order to identify disease-relevant biological pathways and potential drug targets. Based on those newly discovered drug targets, the collaboration has now identified a number of promising drug candidates to rapidly bring forward to lab-based validation to determine the full potential of these assets.
To read the full RNS click here
Highlights
Poolbeg Pharma , a leading infectious disease focused biopharmaceutical company, announces that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus ('RSV') artificial intelligence ('AI') Programme with OneThree Biotech, Inc.
Since initiating the collaboration in February 2022, Poolbeg's scientific team has worked closely with OneThree to build a tailored AI approach that leverages Poolbeg's unique RSV human challenge trial data in order to identify disease-relevant biological pathways and potential drug targets. Based on those newly discovered drug targets, the collaboration has now identified a number of promising drug candidates to rapidly bring forward to lab-based validation to determine the full potential of these assets.
To read the full RNS click here